We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
-14.15%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$5.67B
AUM Growth
-$1.54B
(-21%)
Cap. Flow
+$155M
Cap. Flow
% of AUM
2.74%
Top 10 Holdings %
Top 10 Hldgs %
45.45%
Holding
105
New
10
Increased
9
Reduced
7
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
LIAN
LianBio American Depositary Shares
LIAN
|
+$87.4M |
| 2 |
BLU
BELLUS Health Inc.
BLU
|
+$67.9M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$59.2M |
| 4 |
Relmada Therapeutics
RLMD
|
+$44.5M |
| 5 |
Xilio Therapeutics
XLO
|
+$34.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Atea Pharmaceuticals
AVIR
|
+$190M |
| 2 |
TG Therapeutics
TGTX
|
+$49M |
| 3 |
VERV
Verve Therapeutics
VERV
|
+$23.9M |
| 4 |
CytomX Therapeutics
CTMX
|
+$17.8M |
| 5 |
WHWK
Whitehawk Therapeutics
WHWK
|
+$10.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.88% |
| 2 | Financials | 0.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma A/S
ASND
$16.6B
| $1.02B | 17.95% |
7,567,900
+180,000
| +2% | +$26.8M |
|
2
Novavax
NVAX
$1.22B
| $300M | 5.29% |
2,097,794
| – | – |
|
|
ITOS
3
DELISTED
iTeos Therapeutics
ITOS
| $206M | 3.63% |
4,417,259
| – | – |
|
4
Travere Therapeutics
TVTX
$5.29B
| $174M | 3.07% |
5,614,428
| – | – |
|
5
Janux Therapeutics
JANX
$922M
| $171M | 3.02% |
8,670,644
| – | – |
|
6
Cytek Biosciences
CTKB
$566M
| $157M | 2.76% |
9,607,028
| – | – |
|
|
IMGN
7
DELISTED
Immunogen Inc
IMGN
| $150M | 2.65% |
20,241,458
+1,824,000
| +10% | +$11.3M |
|
|
CLYM
8
Climb Bio
CLYM
$708M
| $138M | 2.43% |
13,150,849
| – | – |
|
|
ICVX
9
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $132M | 2.33% |
5,779,347
| – | – |
|
|
DICE
10
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $132M | 2.32% |
5,208,911
| – | – |
|
11
Vor Biopharma
VOR
$1.08B
| $129M | 2.28% |
556,049
| – | – |
|
|
FMTX
12
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $128M | 2.26% |
9,011,651
| – | – |
|
13
Tyra Biosciences
TYRA
$1.87B
| $102M | 1.8% |
7,236,454
| – | – |
|
14
Vaxcyte
PCVX
$7.71B
| $101M | 1.78% |
4,240,464
+343,599
| +9% | +$7.99M |
|
15
MacroGenics
MGNX
$238M
| $98M | 1.73% |
6,103,594
+160,000
| +3% | +$3.01M |
|
|
JBIO
16
Jade Biosciences
JBIO
$1.21B
| $97.4M | 1.72% |
236,114
| – | – |
|
17
Nkarta
NKTX
$153M
| $86M | 1.52% |
5,605,129
| – | – |
|
|
DAWN
18
DELISTED
Day One Biopharmaceuticals
DAWN
| $83.7M | 1.48% |
4,965,588
| – | – |
|
19
Instil Bio
TIL
$48.9M
| $83.3M | 1.47% |
243,540
| – | – |
|
|
BLU
20
DELISTED
BELLUS Health Inc.
BLU
| $82.4M | 1.45% |
+10,230,274
| New | +$67.9M |
|
21
Celldex Therapeutics
CLDX
$2.91B
| $69.7M | 1.23% |
1,804,795
+204,795
| +13% | +$8.92M |
|
22
Tenaya Therapeutics
TNYA
$160M
| $67.3M | 1.19% |
3,551,508
| – | – |
|
23
GH Research
GHRS
$1.94B
| $66.3M | 1.17% |
2,843,757
-170,200
| -6% | -$3.74M |
|
24
Acumen Pharmaceuticals
ABOS
$155M
| $66M | 1.16% |
9,770,773
| – | – |
|
|
ETNB
25
DELISTED
89bio
ETNB
| $64.9M | 1.14% |
4,965,769
| – | – |
|
Similar funds
RCMNY
SCM
SIM
NPT
AC
PVI
WPL
BAMF
RA Capital Management's Q4 2021 Portfolio in Review
As of Q4 2021, RA Capital Management held 105 positions worth $5.67B, down 21% from $7.22B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
RA Capital Management's Q4 2021 filing shows 10 new, 9 increased, 7 reduced and 8 closed positions. Its largest new stake was LianBio American Depositary Shares: 7,655,015 shares worth $47.2M. The largest sale was Atea Pharmaceuticals, an estimated $190M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.
- RA Capital Management's largest Q4 2021 buy was LianBio American Depositary Shares: 7,655,015 shares worth $47.2M.
- RA Capital Management added most to Ascendis Pharma A/S in Q4 2021, an estimated $26.8M increase.
- RA Capital Management's biggest Q4 2021 reduction was TG Therapeutics, cutting an estimated $49M.
- RA Capital Management fully exited Atea Pharmaceuticals in Q4 2021, selling an estimated $190M.
- RA Capital Management's ten largest holdings make up 45% of its $5.67B portfolio in Q4 2021.
- RA Capital Management opened 10 new positions and closed 8 in Q4 2021.
- RA Capital Management's portfolio value fell 21% quarter-over-quarter to $5.67B.
Based on RA Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.